nifekalant hydrochloride has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirayama, A; Kofune, M; Mano, H; Nagashima, K; Ohkubo, K; Okumura, Y; Sonoda, K; Watanabe, I | 1 |
| Kofune, T; Masaki, R; Okubo, K; Okumura, Y; Saito, S; Shindo, A; Watanabe, I | 1 |
2 other study(ies) available for nifekalant hydrochloride and Chronic Disease
| Article | Year |
|---|---|
Pharmacologic atrial defibrillation by drug delivery into the temporarily occluded coronary sinus. A canine study.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Balloon Occlusion; Cardiac Pacing, Artificial; Chronic Disease; Coronary Sinus; Dogs; Drug Delivery Systems; Injections, Intravenous; Lidocaine; Pyrimidinones; Treatment Outcome | 2012 |
Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershock; Female; Heart Atria; Heart Rate; Humans; Male; Middle Aged; Pyrimidinones; Refractory Period, Electrophysiological | 2005 |